GenVec is an entrepreneurial clinical-stage biopharmaceutical company focused on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product, CGF166, is licensed to Novartis and currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, the company also licenses its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Company Details
- Founded
- -
- Address
- 910 Clopper Road, Suite 220n, Gaithersburg,md 20878,united States
- Phone
- 3019441894
- cb****@****vec.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- genvec.com
- Keywords
- Rockville.
- HQ
- Gaithersburg, MD
Genvec Questions
Genvec's helpline number is 3019441894
Genvec's website is genvec.com
Genvec's LinkedIn profile is https://www.linkedin.com/company/genvec
Genvec's industry is
Biotechnology Research
Genvec's top competitors are
Medispec,
Emergent Biosolutions,
Macrogenics, Inc.,
Novavax,
Celltrion Inc,
Samsung Biologics,
Medimmune,
Dp Clinical Inc.,
Precigen,
Regenxbio.
Genvec's support email address is cbyroad@genvec.com
Genvec's categories are Biotechnology Research
Genvec's founding year is 1992
